Today marks a significant milestone for Immunome and for the desmoid tumor community. We are proud to announce the submission of a New Drug Application (NDA) to the U.S. FDA for varegacestat — an investigational, once daily, oral, gamma-secretase inhibitor. The results from the phase 3 RINGSIDE trial highlight the progress we are making toward our mission to redefine the standard of care for desmoid tumors. To the RINGSIDE trial patients, families, investigators, study site teams, and patient advocacy partners — thank you for making this possible. Read more here: https://lnkd.in/giZHBa_9 The Desmoid Tumor Research Foundation (DTRF) The Desmoid Project Sarcoma Patient Advocacy Global Network (SPAGN) SARC-Sarcoma Alliance for Research through Collaboration
Immunome, Inc.
Biotechnology Research
Bothell, Washington 12,996 followers
Transformative Targeted Therapies
About us
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
- Website
-
https://www.immunome.com/
External link for Immunome, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Bothell, Washington
- Type
- Public Company
- Specialties
- Biotechnology
Locations
-
Primary
Get directions
18702 North Creek Pkwy
100
Bothell, Washington 98011, US
Employees at Immunome, Inc.
Updates
-
We’re on a mission to help transform the treatment landscape for people living with desmoid tumors. At the 2026 ASCO Annual Meeting, we will be presenting data from our global pivotal Phase 3 RINGSIDE trial. These findings have the potential to redefine the standard of care for patients with desmoid tumors. Learn more here: https://lnkd.in/gcpaR4MZ
-
Immunome, Inc. reposted this
📣 It’s time to Spread the Word! Last year, we came together to correct a critical misconception that desmoid tumors are NOT benign. This year, we are building on that momentum to go one step further and make sure the correct classification of desmoid tumors is front and center. ⭐️ According to the World Health Organization (WHO), desmoid tumors are classified as intermediate, locally aggressive tumors (see Table II- Fibroblastic/Myofibroblastic Tumours): https://lnkd.in/gw5VAGSD The medical community and research sources often use inconsistent language to describe desmoid tumors, creating confusion for patients and clinicians that can impact treatment decisions and minimize the seriousness of this rare disease. 💬 You can help Spread the Word today by liking, commenting, and sharing this post with your community. 🔗 Visit DTRF’s “What is a desmoid tumor?” page for more info: https://lnkd.in/e7X-Wb4h #DesmoidsareNOTbenign #SpreadtheWord #DTRF #DesmoidTumorResearchFoundation #desmoid #desmoidtumor #desmoidawareness #aggressivefibromatosis #desmoidresearch #FAP #familialadenomatouspolyposis #raredisease
-
-
Immunome Announces Positive Topline Results from Phase 3 Trial of Varegacestat in Patients with Desmoid tumors: Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a manageable safety profile New Drug Application submission to U.S. FDA planned for Q2 2026 Company to host conference call today, December 15, at 8:30 a.m. ET View the entire press release here: https://lnkd.in/gzNZ_EWU
-
Immunome's CEO Dr. Clay Siegall reveals the 3 things that make it exciting to work at Immunome. #patientimpact #defeatcancer #teamimmunome
-
Immunome Reported Third Quarter 2025 Financial Results and Provided a Business Update: “Immunome’s pipeline continues to advance,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We anticipate the release of topline data for the RINGSIDE trial of varegacestat before the end of this year, to be followed by an NDA submission if warranted.” Read the press release: https://lnkd.in/g3KGmB4K
-
Our Chief Business Officer Kinney Horn talks about why he's excited about the future of Immunome as our team presents at the Triple Meeting in Boston.
-
Immunome recently presented preclinical data showing its proprietary antibody-drug conjugate (ADC) payload HC74 overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is a novel topoisomerase I inhibitor that serves as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors, and as the payload in several preclinical candidates within the Immunome pipeline. Read the full release here: https://lnkd.in/gmXP-RuN